Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 3/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995132 | 0.82 | MAPT (0.62) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL4768431 | 0.81 | CTSB (0.42) | MAPTHTTL3MBTL1PGK1NPC1 | |
| SCHEMBL17483844 | 0.80 | MAPT (0.63) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL30154422 | 0.80 | MAPT (0.67) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL1978817 | 0.80 | MAPT (0.67) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL8246245 | 0.80 | MAPT (0.59) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL9041749 | 0.80 | MAPT (0.59) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL12958927 | 0.78 | MAPT (0.65) | MAPTHTTFGFR4MERTKGSR | |
| SCHEMBL11653146 | 0.78 | MAPT (0.58) | MAPTHTTFGFR4GSRTXNRD1 | |
| SCHEMBL3813745 | 0.78 | MAPT (0.57) | MAPTHTTFGFR4CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1945304-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007048843-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048843-A2 | IMIDAZO-PYRIDINE CONTAINING BETA AGONISTS, METHOD FOR PRODUCING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | ADRB3, ADRB2, ADRB1 | MAPT 4073/4885HTT 3985/4885FGFR4 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.